Volume 8, Issue 2 (4-2026)
pbp 2026, 8(2): 222-232 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kamkari S, Aghdaki M. Nanoparticles in the Treatment of Uterine Fibroids: Evidence from Animal and Human Cell Studies. pbp 2026; 8 (2) :222-232
URL: http://pbp.medilam.ac.ir/article-1-393-en.html
URL: http://pbp.medilam.ac.ir/article-1-393-en.html
1- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran ,maryam.aghdaki@yahoo.com
2- Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran ,
Abstract: (2961 Views)
Introduction: Uterine fibroids are the most prevalent benign tumors among premenopausal women, often presenting with heavy menstrual bleeding, anemia, pelvic pain, and infertility. Conventional treatments, including surgical interventions and systemic pharmacotherapy, are frequently limited by adverse effects and incomplete efficacy. Recent studies have emphasized the potential of nanoparticles as targeted drug delivery systems, offering enhanced drug stability and bioavailability, reduced dosages, and improved therapeutic outcomes. This review aims to examine the primary types of nanoparticles utilized in the treatment of uterine fibroids.
Methods: A systematic search of PubMed, Scopus, Google Scholar, and Web of Science was conducted to identify studies published between 2010 and 2025 that investigated the use of nanoparticles in uterine fibroid therapy. Keywords included “uterine fibroid,” “nanoparticles,” “therapy,” and related combinations. Both animal models and human cell studies were considered, with extracted data encompassing nanoparticle type, experimental model, dosage, therapeutic outcomes, and safety profiles, summarized in a comprehensive table. Review articles and preclinical studies lacking sufficient data were excluded.
Results: The analysis revealed that metallic and polymeric nanoparticles effectively reduced fibroid growth, suppressed Ki67 expression, and promoted apoptosis while enabling controlled drug release. Magnetic and peptide-based nanoparticles improved the efficiency of HSV-TK suicide gene delivery and selectively inhibited fibroid cell proliferation. Liposomal and electrospun nanoparticles enhanced cytotoxicity and reactive oxygen species (ROS) generation, modulating proliferation and epithelial-mesenchymal transition (EMT) pathways in a concentration- and drug-dependent manner.
Conclusion: Nanoparticles represent a promising, minimally invasive approach for uterine fibroid management. Various nanoparticle classes—including metallic, polymeric, magnetic, peptide-based, and liposomal systems have demonstrated significant therapeutic effects in both animal models and human cell studies. However, clinical research remains limited, and long-term safety assessments are essential. Future studies should focus on pharmacokinetics, optimal dosing, and potential adverse effects in humans to facilitate the translation of these technologies into clinical practice.
Methods: A systematic search of PubMed, Scopus, Google Scholar, and Web of Science was conducted to identify studies published between 2010 and 2025 that investigated the use of nanoparticles in uterine fibroid therapy. Keywords included “uterine fibroid,” “nanoparticles,” “therapy,” and related combinations. Both animal models and human cell studies were considered, with extracted data encompassing nanoparticle type, experimental model, dosage, therapeutic outcomes, and safety profiles, summarized in a comprehensive table. Review articles and preclinical studies lacking sufficient data were excluded.
Results: The analysis revealed that metallic and polymeric nanoparticles effectively reduced fibroid growth, suppressed Ki67 expression, and promoted apoptosis while enabling controlled drug release. Magnetic and peptide-based nanoparticles improved the efficiency of HSV-TK suicide gene delivery and selectively inhibited fibroid cell proliferation. Liposomal and electrospun nanoparticles enhanced cytotoxicity and reactive oxygen species (ROS) generation, modulating proliferation and epithelial-mesenchymal transition (EMT) pathways in a concentration- and drug-dependent manner.
Conclusion: Nanoparticles represent a promising, minimally invasive approach for uterine fibroid management. Various nanoparticle classes—including metallic, polymeric, magnetic, peptide-based, and liposomal systems have demonstrated significant therapeutic effects in both animal models and human cell studies. However, clinical research remains limited, and long-term safety assessments are essential. Future studies should focus on pharmacokinetics, optimal dosing, and potential adverse effects in humans to facilitate the translation of these technologies into clinical practice.
Keywords: Uterine fibroids, Nanoparticles, Drug delivery systems, Gene therapy, Apoptosis, Targeted therapy
Type of Study: Review/Systemtic review |
Subject:
Pharmacological
Received: 2025/09/28 | Accepted: 2026/02/8 | Published: 2026/01/1
Received: 2025/09/28 | Accepted: 2026/02/8 | Published: 2026/01/1
References
1. Kamkari S, Soufizadeh Balaneji S. The Role of Medicinal Plants in Relieving Menopausal Symptoms: A Traditional Iranian Medicine Perspective. Plant Biotechnology Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-382-en.html
2. Najib FS, Izanloo E, Aghdaki M, Khansalar S, Fattahi MJ, Oveisi Z, Haghshenas MR. Stromal Cell-Derived Factor1 Genetic Variation at Locus 801 in Patients with Endometrial Cancer. Middle East Journal of Cancer. 2025 Apr 1;16(2):181-8.
3. Kamkari S, Sadat Najib F. Abortifacient Medicinal Plants: A Review of Toxic Herbs During Pregnancy. Plant Biotechnology Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-378-en.html
4. Faraji A, Aghdaki M, Hessami K, Hosseinkhani A, Roozmeh S, Asadi N, et al. Episiotomy wound healing by Commiphora myrrha (Nees) Engl. and Boswellia carteri Birdw. in primiparous women: A randomized controlled trial. Journal of Ethnopharmacology. 2021 Jan 10;264:113396.
5. Aghdaki M, Kamkari S. Probiotics as a Therapeutic Strategy in Ovarian Cancer: Insights from Preclinical and Clinical Evidence. Plant Biotechnology Persa. 2026;8. Available from: http://pbp.medilam.ac.ir/article-1-392-en.html
6. Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E. Global socioeconomic inequalities in breast, cervical, ovarian, and uterine cancers incidence, mortality, disability-adjusted life year’s rates: a relative concentration index analysis. BMC Women's Health. 2025 Sep 25;25(1):433.
7. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven BJ. Uterine fibroids. Nature Reviews Disease Primers. 2016 Jun 23;2(1):1-8.
8. McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. Seminars in Reproductive Medicine. 2017 Mar;35(2):181-189.
9. Slabozhankina EA, Kira EF, Politova AK, Kitaev VM, Amelina UL, Politova AA. Modern concepts of etiology and pathogenesis of uterine fibroid. Meditsinskiy Vestnik Bashkortostana. 2021;86.
10. Sefah N, Ndebele S, Prince L, Korasare E, Agbleke M, Nkansah A, et al. Uterine fibroids—Causes, impact, treatment, and lens to the African perspective. Frontiers in Pharmacology. 2023 Jan 10;13:1045783.
11. AlAshqar A, Lulseged B, Mason-Otey A, Liang J, Begum UA, Afrin S, et al. Oxidative stress and antioxidants in uterine fibroids: pathophysiology and clinical implications. Antioxidants. 2023 Mar 26;12(4):807.
12. Otify M, Critchley HO. Pathophysiology of uterine fibroids. Modern Management of Uterine Fibroids. 2020 Dec 3;1.
13. De La Cruz MS, Buchanan EM. Uterine fibroids: diagnosis and treatment. American Family Physician. 2017 Jan 15;95(2):100-7.
14. Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: an update on current and emerging medical treatment options. Therapeutics and Clinical Risk Management. 2019 Jan 23;15:157-78.
15. Shiri S, Alizadeh K, Abbasi N. A novel technique for simultaneous determination of drugs using magnetic nanoparticles-based dispersive micro-solid-phase extraction in biological fluids and wastewaters. MethodsX. 2020;7:101040. doi:10.1016/j.mex.2020.100952
16. Spencer DS, Puranik AS, Peppas NA. Intelligent nanoparticles for advanced drug delivery in cancer treatment. Current Opinion in Chemical Engineering. 2015 Feb 1;7:84-92.
17. Öztürk K, Eroğlu H, Çalış S. Novel advances in targeted drug delivery. Journal of Drug Targeting. 2018 Sep 14;26(8):633-42.
18. Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, et al. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials. 2022 Dec 19;12(24):4494.
19. Kiyimba K, Ahmed A, Choudhary MI, Rehman K, Hasan SM, Jabbar A, et al. Green synthesized Polyscias fulva silver nanoparticles ameliorate uterine fibroids in female Wistar Albino rats. PLOS ONE. 2025 May 9;20(5):e0323260.
20. Shalaby SM, Khater MK, Perucho AM, Mohamed SA, Helwa I, Laknaur A, et al. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertility and Sterility. 2016 Jun 1;105(6):1638-48.
21. Al Enazy S, Kirschen GW, Vincent K, Yang J, Saada J, Shah M, et al. PEGylated polymeric nanoparticles loaded with 2-methoxyestradiol for the treatment of uterine leiomyoma in a patient-derived xenograft mouse model. Journal of Pharmaceutical Sciences. 2023 Sep 1;112(9):2552-60.
22. Öner ET, Kandur M, Bahadori F. Biomedical and Pharmaceutical Approaches for Uterine Fibroids: Current Methods and Recent Developments. Authorea Preprints. 2023 Jul 13.
23. El Sabeh M, Vincent KL, Afrin S, Motamedi M, Saada J, Yang J, et al. Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. Journal of Obstetrics and Gynaecology Research. 2022 Aug 18;42(6):2139-43.
24. Upadhyay S, Bhushan R, Pandey V, Tripathi A, Sahu AN, Rani A, et al. A comparative analysis of phytochemicals vs synthetic drugs/nanomedicines in the treatment of uterine fibroid: A Systematic Review. [Journal not specified].
25. Al-Enazy S, Kirschen GW, Vincent K, Yang J, Saada J, Shah M, et al. PEGylated Nanoparticles Loaded with 2-Methoxyestradiol for the Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model. [Journal not specified].
26. Borahay MA, Vincent KL, Motamedi M, Tekedereli I, Salama SA, Ozpolat B, et al. Liposomal 2-methoxyestradiol nanoparticles for treatment of uterine leiomyoma in a patient-derived xenograft mouse model. Reproductive Sciences. 2021 Jan;28(1):271-7.
27. Shtykalova S, Egorova A, Maretina M, Baranov V, Kiselev A. Magnetic nanoparticles as a component of peptide-based DNA delivery system for suicide gene therapy of uterine leiomyoma. Bioengineering. 2022 Mar 8;9(3):112.
28. Egorova A, Selutin A, Maretina M, Selkov S, Kiselev A. Peptide-based nanoparticles for αvβ3 integrin-targeted DNA delivery to Cancer and Uterine Leiomyoma cells. Molecules. 2022 Nov 30;27(23):8363.
29. Song W. Electrochemical Sensor for Detection of Mifepristone and Cinnamic Acid for Treatment of Uterine Fibroids using Immobilized Double-Stranded DNA on the AuNPs Modified Glassy Carbon Electrode. International Journal of Electrochemical Science. 2022 May 1;17(5):220564.
30. Shtykalova S, Egorova A, Selutin A, Freund S, Maretina M, Baranov V, Kiselev A. Development of RGD-conjugated peptide-based polyplexes with anionic coating for delivery of herpes thymidine kinase gene to uterine fibroids cells. [Journal not specified].
31. Jiang J, Bischof J. Effect of timing, dose and interstitial versus nanoparticle delivery of tumor necrosis factor alpha in combinatorial adjuvant cryosurgery treatment of ELT-3 uterine fibroid tumor. CryoLetters. 2010 Jan 1;31(1):50-62.
32. Aparajay P, Madhyastha H, Bhowmik S, Dev A. In vitro apoptotic potential and ex vivo permeation analysis of ulipristal acetate loaded niosomes for management of uterine fibroids. Journal of Microencapsulation. 2025 Aug 18;42(6):580-92.
33. Wang J, Wang Q, Liu J. Effects of Recepteur D’origine Nantais/Phosphatidylinositol 3 Kinase Pathway Mediated by Polymer Biodegradable Sustained-Release Materials on Proliferation and Apoptosis of Uterine Fibroids. Science of Advanced Materials. 2023 Oct 1;15(10):1343-50.
34. Borahay MA, Vincent KL, Motamedi M, Tekedereli I, Salama SA, Ozpolat B, et al. Liposomal 2-methoxyestradiol nanoparticles for treatment of uterine leiomyoma in a patient-derived xenograft mouse model. Reproductive Sciences. 2021 Jan;28(1):271-7.
35. Egorova A, Selutin A, Maretina M, Selkov S, Kiselev A. Peptide-based nanoparticles for αvβ3 integrin-targeted DNA delivery to Cancer and Uterine Leiomyoma cells. Molecules. 2022 Nov 30;27(23):8363.
36. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Human Reproduction Update. 2016 Nov 20;22(6):665-86.
37. Upadhyay S, Pandey V, Tripathi A, Sahu AN, Rani A, Diwakar A, Chaubey L, Gupta R, Dubey PK. A comparative analysis of phytochemicals versus synthetic drugs/nanomedicines in the treatment of uterine fibroid: a systematic review. Toxicology and Environmental Health Sciences. 2024 Mar;16(1):21-36.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |